Tests imzokitug with pumitamig and chemotherapy for advanced lung cancer
Tests imzokitug added to pumitamig and chemotherapy in adults with advanced lung cancer.
Plain-language title generated from the registry record
Registry title: A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Key facts
- Where
- Santiago and Viña del Mar, ChileSee the 3 sites
- Phase
- Phase 2
Where in Chile
- BradfordhillSantiago, ChileTaking people
- Orlandi OncologiaSantiago, ChileTaking people
- Oncocentro ApysViña del Mar, ChileTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07680764EU 2026-525170-19-00
- Record updated
- 23 October 2026
- Original description
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Read full original descriptionShow less
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Inclusion: Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition; Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease; Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site; Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1; Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exclusion: Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated; Participants must not have prior treatment with immuno-oncology therapies; Participants must not have untreated central nervous system (CNS) metastases; Other protocol-defined Inclusion/Exclusion criteria apply.